In Vivo Targeting of T-Cells with Antibody- and Cytokine Conjugated Liposomes

The invention provides compositions and methods for, inter alia, augmenting cell-based therapies in vivo by repeatedly stimulating target cells of interest over a period of time.

Researchers

Yiran Zheng / Yuan Zhang / Brandon Kwong / Darrell J Irvine

Departments: David H Koch Institute for Integrative Cancer Res
Technology Areas: Biotechnology: Cell Separation, Sensors & Monitoring / Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living

  • in vivo targeting of cells with ligand-conjugated particles
    European Patent Convention | Granted | 3,010,528
  • in vivo targeting of t-cells with ligand-conjugated particles
    Canada | Published application
  • in vivo targeting of cells with ligand-conjugated particles
    Switzerland | Granted | 3,010,528
  • in vivo targeting of cells with ligand-conjugated particles
    Germany | Granted | 3,010,528
  • in vivo targeting of cells with ligand-conjugated particles
    France | Granted | 3,010,528
  • in vivo targeting of cells with ligand-conjugated particles
    United Kingdom | Granted | 3,010,528
  • in vivo targeting of cells with ligand-conjugated particles
    Italy | Granted | 3,010,528
  • in vivo targeting of cells with ligand-conjugated particles
    Netherlands | Granted | 3,010,528
  • in vivo targeting of cells with ligand-conjugated particles
    Sweden | Granted | 3,010,528
  • in vivo targeting of cells with ligand-conjugated particles
    United States of America | Published application

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.